Gerald Minuk

2.9k total citations · 1 hit paper
8 papers, 2.3k citations indexed

About

Gerald Minuk is a scholar working on Epidemiology, Hepatology and Rheumatology. According to data from OpenAlex, Gerald Minuk has authored 8 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 6 papers in Hepatology and 2 papers in Rheumatology. Recurrent topics in Gerald Minuk's work include Liver Disease Diagnosis and Treatment (7 papers), Hepatitis C virus research (5 papers) and Hepatitis B Virus Studies (2 papers). Gerald Minuk is often cited by papers focused on Liver Disease Diagnosis and Treatment (7 papers), Hepatitis C virus research (5 papers) and Hepatitis B Virus Studies (2 papers). Gerald Minuk collaborates with scholars based in Canada, Italy and Germany. Gerald Minuk's co-authors include Patrick Marcellin, Jenny Heathcote, Stefan Zeuzem, C. Trépo, Vincent G. Bain, G. Idéo, Samuel S. Lee, Christian Niederau, Janice K. Albrecht and Thierry Poynard and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Journal of Hepatology.

In The Last Decade

Gerald Minuk

8 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

1998 1.9k citations Thierry Poynard, Patrick Marcellin et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gerald Minuk Canada	5	2.0k	2.0k	212	171	168	8	2.3k
J. Moussalli France	24	2.3k 1.2×	2.3k 1.2×	126 0.6×	76 0.4×	132 0.8×	56	2.7k
Marie–Pierre Ripault France	20	2.2k 1.1×	2.2k 1.1×	147 0.7×	87 0.5×	131 0.8×	34	2.5k
Rami Moucari France	26	2.6k 1.3×	2.5k 1.3×	128 0.6×	125 0.7×	184 1.1×	49	2.9k
David Sheridan United Kingdom	15	2.2k 1.1×	2.3k 1.1×	413 1.9×	315 1.8×	145 0.9×	36	2.9k
Dominique Capron France	17	701 0.4×	830 0.4×	82 0.4×	149 0.9×	94 0.6×	43	1.1k
Massimo Colombo Italy	15	1.3k 0.6×	1.6k 0.8×	76 0.4×	337 2.0×	73 0.4×	26	2.0k
Johan Westin Sweden	21	1.5k 0.8×	1.4k 0.7×	247 1.2×	30 0.2×	84 0.5×	50	1.8k
Kelly Kaita Canada	19	756 0.4×	887 0.4×	56 0.3×	180 1.1×	97 0.6×	49	1.2k
M.P. Manns Germany	24	970 0.5×	937 0.5×	141 0.7×	77 0.5×	148 0.9×	131	2.0k
Antonio Ascione Italy	19	1.5k 0.7×	1.4k 0.7×	68 0.3×	65 0.4×	95 0.6×	53	1.7k

Countries citing papers authored by Gerald Minuk

Since Specialization

Citations

This map shows the geographic impact of Gerald Minuk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald Minuk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald Minuk more than expected).

Fields of papers citing papers by Gerald Minuk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald Minuk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald Minuk. The network helps show where Gerald Minuk may publish in the future.

Co-authorship network of co-authors of Gerald Minuk

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald Minuk. A scholar is included among the top collaborators of Gerald Minuk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald Minuk. Gerald Minuk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Uhanova, Julia, et al.. (2020). Chronic Liver Disease and Metabolic Comorbidities in Healthy Young Males Followed for 65 Years: The Manitoba Follow-up Study. Clinical Gastroenterology and Hepatology. 19(11). 2417–2424.e2. 4 indexed citations

2.

Muir, Andrew J., Zachary Goodman, Christopher L. Bowlus, et al.. (2016). Serum LYSYL Oxidase-Like-2 (SLOXL2) Levels Correlate with Disease Severity in Patients with Primary Sclerosing Cholangitis. Journal of Hepatology. 64(2). S428–S428. 7 indexed citations

3.

Pockros, Paul J., Robert L. Carithers, Paul Desmond, et al.. (2004). Efficacy and Safety of Two-Dose Regimens of Peginterferon Alpha-2a Compared with Interferon Alpha-2a in Chronic Hepatitis C: A Multicenter, Randomized Controlled Trial. The American Journal of Gastroenterology. 99(7). 1298–1305. 64 indexed citations

4.

Assy, Nimer, et al.. (2000). Fatty Infiltration of Liver in Hyperlipidemic Patients. Digestive Diseases and Sciences. 45(10). 1929–1934. 294 indexed citations

5.

Collier, Jane, Paul A. Adams, Cameron N. Ghent, et al.. (2000). Long Term Follow-Up of Patients with Chronic Hepatitis C Treated with Alpha Interferon. SHILAP Revista de lepidopterología. 14(suppl b). 77B–81B. 4 indexed citations

6.

Kaita, Kelly, et al.. (2000). Early Changes in Hepatitis C Virus (HCV) RNA Levels Predict Response to Interferon Treatment in Non-Cirrhotic HCV Patients. SHILAP Revista de lepidopterología. 14(suppl b). 30B–35B. 4 indexed citations

7.

Poynard, Thierry, Patrick Marcellin, Samuel S. Lee, et al.. (1998). Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. European Journal of Gastroenterology & Hepatology. 10(12). 1063–1063. 42 indexed citations

8.

Poynard, Thierry, Patrick Marcellin, Samuel S. Lee, et al.. (1998). Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. The Lancet. 352(9138). 1426–1432. 1908 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact